Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00392054 · ClinicalTrials.gov registry record · Phase 3
First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study)
A Phase 3 study, sponsored by Population Health Research Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 127
- Enrollment target
NCT00392054 is a Phase 3 study that has completed, run by Population Health Research Institute. The registered enrollment target is 127 participants.
The verdict
NCT00392054, a Phase 3 study, has completed, sponsored by Population Health Research Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 127 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether catheter-based pulmonary vein isolation is superior to antiarrhythmic drugs as first line therapy in patients with symptomatic paroxysmal recurrent atrial fibrillation not previously treated with therapeutic doses of antiarrhythmic drugs.
Interventions
- PROCEDURE Pulmonary Vein Isolation performed by Catheter Ablation
- DRUG Conventional Antiarrhythmic Drug Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2006-08 |
| Est. Completion | 2012-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00392054
The ClinicalTrials.gov registry entry for NCT00392054 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Population Health Research Institute, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pulmonary Vein Isolation performed by Catheter Ablation is the first listed.
NCT00392054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00392054 about?
NCT00392054 is a clinical study titled "First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study)". The purpose of this study is to determine whether catheter-based pulmonary vein isolation is superior to antiarrhythmic drugs as first line therapy in patients with symptomatic paroxysmal recurrent atrial fibrillation not previously treated with therapeutic doses of antiarrhythmic drugs.
What is the current status of trial NCT00392054?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 127 participants. The study started on 2006-08. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00392054?
The interventions under investigation include: Pulmonary Vein Isolation performed by Catheter Ablation (PROCEDURE), Conventional Antiarrhythmic Drug Therapy (DRUG).
Who is sponsoring clinical trial NCT00392054?
This trial is sponsored by Population Health Research Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.